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endogenous enzymatic or nonenzymatic scavengers
such as superoxide dismutase, catalase, or glutathione.
However, there are no such scavengers for the highly
reactive and cytotoxic hydroxyl radical, which may irre-
versibly damage cells by lipid peroxidation and alter-
ation of protein structures.2 This radical is generated
from the superoxide anion and hydrogen peroxide in the
presence of trace amounts of transition metal ions of
iron or copper via the metal catalyzed Haber-Weiss reac-
tion.3 In addition, iron is thought to be necessary for the
propagation of lipid peroxidation after its initiation by
the hydroxyl radical.4 Specific chelators for transition
metals such as desferrioxamine (DFO) can tightly bind
iron and copper. This effect modulates the redox poten-
Reactive oxygen-derived intermediates such as hydro-gen peroxides, superoxide anions, and hydroxyl rad-
icals play an important role in postischemic myocardial
injury.1 Both superoxide anions and hydrogen peroxides
are relatively weak oxidants that are neutralized by
Objective: Traces of redox-active transition metals such as iron and copper
play an important role in free radical formation during postischemic reper-
fusion of the heart. Two studies were conducted to assess the efficacy of the
complexes of desferrioxamine with zinc or gallium to prevent this aspect of
reperfusion injury.
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hours of hypothermic arrest at 10°C induced by use of St Thomas’ Hospital
cardioplegic solution II supplemented with desferrioxamine, zinc-histidinate,
zinc-desferrioxamine, gallium-nitrate, or gallium-desferrioxamine. In study
II, isolated nonworking rat hearts (n = 23) were subjected to normothermic
regional (10 minutes) or global (35 minutes) unprotected ischemia. In this
study, the perfusate was supplemented with gallium-desferrioxamine during
preischemic and postischemic periods. 
Results: In study I, the addition of desferrioxamine, zinc-histidinate, or gal-
lium-nitrate to St Thomas’ Hospital solution II improved postischemic aor-
tic flow recovery. When the binary complexes zinc-desferrioxamine or galli-
um-desferrioxamine were added, however, functional recovery was further
enhanced significantly. In study II, high-performance liquid chromatography
analyses of tissue from postischemic hearts exposed to unsupplemented per-
fusate revealed a marked increase of malondialdehydes. In hearts perfused
with perfusate supplemented with gallium-desferrioxamine, however, tissue
malondialdehyde concentrations were significantly smaller, indicating
reduced free radical formation. 
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tial of these metal ions, and therefore several investiga-
tors were able to prove cardioprotective effects of DFO
in experimental and clinical studies.5,6
On the other hand, redox-inactive zinc ions and also
gallium ions compete for the binding sites of redox-
active iron ions, displace them, and divert the site of
hydroxyl radical production.7 Previous studies have
proven that this mechanism is effective for protection
of isolated rat hearts.8 Likewise, gallium disclosed a
protective effect on neonatal rat heart cells subjected to
oxidative stress through inhibition of free radical gen-
eration.9
Because both mechanisms differ in the way they
neutralize the presence of iron, there is reason to
assume synergistic organ protective effects from DFO
in its complexes with zinc or gallium. Recently, they
have been identified as protective against postischemic
reperfusion injury in the cat retina,10 against corneal
alkali injury in rabbits,11 and against x-ray–induced
damage to various tissues.12,13 Because available infor-
mation about the protective capacities of these com-
plexes on the heart is limited, we conducted 2 comple-
mentary experimental studies resembling some aspects
of clinical cardiac surgery. In study I, isolated working
rat hearts were used to assess the effects of zinc-DFO,
gallium-DFO, and their constituents alone on the
reperfusion injury after hypothermic cardioplegic
arrest. In this study, end points included parameters of
cardiac function and cellular damage. In study II, non-
working rat hearts subjected to normothermic regional
or global ischemia were used to assess the effects of
gallium-DFO on tissue concentrations of malondialde-
hydes, which were measured as an index of lipid per-
oxidation. In addition, myocardial concentration
changes in energy-rich phosphates and their metabo-
lites were assessed. 
Materials and methods
Animals. Male Wistar rats (250-400 g) were used in study
I and male Sprague-Dawley rats (250-350 g) in study II.
Animals were housed in specific pathogen-free facilities and
received standard food and water ad libitum before experi-
ments. All animals received humane care in compliance with
the “Principles of Laboratory Animal Care” formulated 
by the National Society of Medical Research and the
“Guide for the Care and Use of Laboratory Animals” pre-
pared by the Institute of Laboratory Animal Resources,
National Research Council, and Published by the National
Academy Press, revised 1996.
Study I
Perfusion procedure. The isolated working rat heart model
was used in study I.14 Rats received sodium heparin (100
IU/100 g body weight) by intraperitoneal injection. After 20
minutes, the rats were anesthetized by inhalation of diethyl
ether. The heart was rapidly excised and placed in ice-cold
saline solution. The aorta was then cannulated and
Langendorff perfusion was initiated at a pressure of 90 cm
H2O with modified Krebs-Henseleit buffer containing (in mil-
limoles per liter) NaCl, 118; KH2PO4, 1.2; KCl, 4.9; CaCl2,
2.5; MgSO4, 1.2; NaHCO3, 25; and glucose, 11.1. The perfu-
sion fluids were filtered through a 5-µm porosity filter to
remove any particulate matter. The perfusate was aerated with
a mixture of 95% oxygen and 5% carbon dioxide (pH 7.4),
and the perfusate temperature was kept at 37°C. During the
time of Langendorff perfusion the left atrium was cannulated
for conversion of the preparation to the working heart mode,
which was achieved by stopping aortic perfusion and starting
left atrial perfusion at a filling pressure of 20 cm H2O. Under
these conditions the perfusate was ejected spontaneously at a
rate of approximately 40 mL/min through the aortic cannula
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Fig 1. Study I: Experimental time course. L, Langendorff perfusion; W, working heart perfusion; CK, creatine
kinase.
against a hydrostatic pressure of 90 cm H2O. Hearts produc-
ing less than 37 mL/min aortic flow were excluded from the
study. Aortic flow was measured by timed collection of the
ejected perfusate in a graduated cylinder. Likewise, coronary
flow was measured by timed collection of the coronary efflu-
ent. The latter fraction of the perfusate was not recycled. After
the measurement of aortic flow, a Millar Mikro-Tip catheter
connected to a pressure transducer (Millar Instruments, Inc,
Houston, Tex) was inserted into the left ventricle through a
rubber-sealed side port of the left atrial cannula for 1 minute
of data acquisition. The left ventricular pressure signal and the
heart rate were recorded and processed online by an analog-
digital converter (Plugsys; Hugo Sachs Electronic, March,
Germany). Data processing was performed by an 80386 IBM-
compatible personal computer equipped with standard labora-
tory software (Haemodyn; Hugo Sachs Electronic).
Time course. After cannulation of the aorta, the heart was
allowed to stabilize for 10 minutes in the Langendorff perfu-
sion mode (Fig 1). After conversion to the working heart
mode, the preparation was perfused for 15 minutes.
Contractile function was measured. All hearts were then sub-
jected to 2 hours of global hypothermic ischemia at 10°C fol-
lowed by 10 minutes of normothermic reperfusion in the
Langendorff mode. During this time period the duration of
ventricular fibrillation until spontaneous conversion to sinus
rhythm was recorded. No defibrillator was used. Then, perfu-
sion was converted to the working heart mode and functional
recovery was assessed 15 minutes later. Creatine kinase leak-
age was measured in the coronary effluent collected during
the initial 5-minute period of preischemic working heart
mode and also during the postischemic Langendorff and
working heart perfusion periods. A standard enzymatic test
based on spectrophotometric measurement of the amount of
nicotinamide adenine dinucleotide phosphate (Granutest 2.5;
Merck, Darmstadt, Germany) was used.15
Protocol. In hearts protected according to experimental
protocol 1, hypothermic cardioplegic arrest was initially
induced by 5 minutes of coronary perfusion with St
Thomas’ Hospital cardioplegic solution II (ST) at 10°C via
a sidearm of the aortic cannula. The content of ST is as fol-
lows (in millimoles per liter): sodium, 120.0; potassium,
16.0; calcium, 1.2; magnesium, 16.0; chloride, 160.4;
bicarbonate, 10.0. During ischemia, hearts were subjected
to 6 cycles of 15 minutes of no flow followed by 5 minutes
of hypothermic perfusion with the same perfusate as used
for induction of ischemia. Depending on the experimental
group, 8 experiments per group were performed with ST
alone or supplemented with DFO (50 µmol/L), zinc-histid-
inate (30 µmol/L), zinc-DFO (5 µmol/L), gallium-nitrate
(100 µmol/L), or gallium-DFO (5 µmol/L). Protocol 2 dif-
fered from protocol 1 in that the initial coronary perfusion
time for induction of cardiac arrest was extended from 5 to
10 minutes. Unlike in protocol 1, there were no reinfusions
during ischemia except for 5 minutes before onset of nor-
mothermic reperfusion, when cardioplegic solution was
readministered. Depending on the experimental group, sup-
plements to the cardioplegic solution were the same as with
protocol 1. 
Study II
Perfusion procedure. The isolated nonworking Langendorff
model was used in study II. Rats were injected with sodium
heparin (500 units intraperitoneally) 30 minutes before anesthe-
sia with sodium pentobarbital (60 mg/kg intraperitoneally). The
heart was rapidly excised and placed in ice-cold saline solution.
After cannulation of the aorta, hearts were perfused in the
Langendorff mode at a pressure of 85 cm H2O with modified
Krebs-Henseleit buffer containing (in millimoles per liter) NaCl,
118; KCl, 5.8; CaCl2, 2.5; MgSO4, 1.2; NaHCO3, 25; and glu-
cose, 11.1. Perfusion fluids were prepared on the day of the
experiment and filtered before use. The perfusate was aerated
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Table I.  Preischemic functional baseline data
Aortic flow Maximum LVDP dP/dtmax Heart rate Coronary flow 
Protection (mL/min) (mm Hg) (mm Hg/s2) (beats/min) (mL/min)
Protocol 1
ST alone 39.5 ± 0.8 160 ± 2 4008 ± 189 287 ± 5 20.2 ± 0.6
ST + DFO 39.8 ± 1.0 153 ± 2 3617 ± 150 291 ± 6 19.5 ± 0.4
ST + Zn 38.8 ± 1.2 150 ± 3 3514 ± 120 282 ± 5 19.3 ± 0.3
ST + Zn-DFO 39.8 ± 0.9 154 ± 3 3623 ± 98 293 ± 3 19.5 ± 0.4
ST + Ga 38.5 ± 0.9 155 ± 2 3620 ± 112 274 ± 4 19.5 ± 0.3
ST + Ga-DFO 39.0 ± 0.7 153 ± 2 3562 ± 101 287 ± 6 18.5 ± 0.5
Protocol 2
ST alone 38.8 ± 1.0 156 ± 3 3812 ± 170 288 ± 7 19.8 ± 0.9
ST + DFO 40.8 ± 0.7 153 ± 2 3639 ± 159 283 ± 4 19.0 ± 0.5
ST + Zn 41.3 ± 0.6 153 ± 3 3450 ± 164 293 ± 3 19.8 ± 0.2
ST + Zn-DFO 38.8 ± 0.6 154 ± 2 3564 ± 166 297 ± 6 20.0 ± 0.3
ST + Ga 38.5 ± 0.9 149 ± 2 3588 ± 96 274 ± 2 19.0 ± 0.4
ST + Ga-DFO 38.8 ± 1.0 150 ± 2 3502 ± 168 295 ± 5 18.5 ± 0.4
LVDP, Left ventricular developed pressure; dP/dtmax, maximum rate of pressure change; ST, St Thomas Hospital cardioplegic solution 2; DFO, desferrioxamine; Zn,
zinc, Ga, gallium.
with a mixture of 95% oxygen and 5% carbon dioxide (pH 7.4),
and the perfusate temperature was kept at 37°C. After function-
al stabilization during 20 minutes of perfusion, hearts were sub-
jected either to 10 minutes of regional ischemia by placing an
occlusive snare around the left anterior descending artery
(groups 2 and 3) or to 35 minutes of no-flow global normother-
mic ischemia (groups 4 and 5). Then, hearts were reperfused for
10 minutes (groups 2 and 3) and 20 minutes (groups 4 and 5)
before they were freeze-clamped with Wollenberger tongs pre-
cooled in liquid nitrogen. The perfusate of hearts in groups 3 and
5 was supplemented with gallium-DFO complex (5 µmol/L)
throughout the experiment, whereas hearts in groups 2 and 4
were perfused with unsupplemented buffer. Another 4 hearts
were freeze-clamped after the stabilization period (group 1).
They served as nonischemic baseline controls. 
High-performance liquid chromatography measurements.
Malondialdehyde, ascorbic acid, adenosine triphosphate,
diphosphate, and monophosphate (ATP, ADP, AMP), and other
nucleotides and nucleosides in heart tissue were determined by
high-performance liquid chromatography (HPLC) from per-
chloric acid extracts prepared under liquid nitrogen. The HPLC
system consisted of a Varian 5000 liquid chromatograph
(Varian Medical Systems, Palo Alto, Calif) equipped with a
Rheodyne 7125 sample injector (20-µL loop) (Rheodyne,
Rohnert Park, Calif) connected to a linear UVIS 200 detector
(UVIS, Reno, Nev). The column used for separation was a 25
cm × 4 mm supersphere 100 RP-18, 4 µm (E. Merck,
Darmstadt, Germany) provided with a guard column packed
with the same matrix as the separative column. The signals
from the detector were acquired on a PC Microsoft MS-DOS
version 5.0 data system (Microsoft Corporation, Redmond,
Wash) and subsequently processed. The mobile phase consist-
ed of 2 eluents: 10 mmol/L tetrabutylammonium hydroxide, 10
mmol/L KH2PO4, 1% methanol, pH 7.0 (buffer A) and 2.8
mmol/L tetrabutylammonium hydroxide, 100 mmol/L
KH2PO4, 30% methanol, pH 5.5 (buffer B).
The gradient for chromatographic separation was as fol-
lows: 26 minutes of 100% of buffer A, 2 minutes at up to 40%
of buffer B, 11 minutes at up to 44% of buffer B, and 10 min-
utes at up to 100% of buffer B that is held for an additional 5
minutes. The initial conditions were restored after 18 minutes
of washing with buffer A. The flow rate was 0.3 mL/min, col-
umn temperature was 18°C, and the detection was performed
at 266 nm, that is, the maximum of adsorption of malondi-
aldehyde and other compounds.16,17
Expression of results. All results are expressed as mean ±
SEM. Creatine kinase leakage, measured during the preis-
chemic control perfusion period and during the first 5 min-
utes of both Langendorff reperfusion and working heart
reperfusion, is expressed as international units per 5 minutes
per heart. Preischemic values of cardiac function, including
aortic flow, maximum left ventricular developed pressure,
maximum rate of pressure change (dP/dtmax), heart rate,
and coronary flow, are expressed in terms of the absolute
values, and indices of postischemic cardiac function are
expressed as a percentage of their individual preischemic
values. The duration of postischemic cardiac fibrillation is
given in seconds. Concentrations of tissue metabolites from
isolated hearts are expressed in micromoles per gram of dry
weight.
Statistical analysis. All multiple comparisons in study I
were performed by analysis of variance. When significant F
values were calculated, intergroup comparisons were per-
formed with Duncan’s test. HPLC data of study II were ana-
lyzed by means of the Mann-Whitney test.
Results 
Study I 
Cardiac function. Table I shows the absolute values
for preischemic cardiac function; no statistically signif-
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Fig 2. Recovery rates of aortic flow in study I (in percent of preischemic value). 1 and 7, ST alone; 2 and 8, ST +
DFO; 3 and 9, ST + zinc; 4 and 10, ST + zinc-DFO; 5 and 11, ST + gallium; 6 and 12, ST + gallium-DFO. Protocol
1, Intermittent cardioplegia; protocol 2, single-shot cardioplegia. †P < .05 versus ST-alone group (protocol 2). 
*P < .05 versus corresponding ST-alone group; **P < .05 versus corresponding groups ST + zinc, ST + gallium,
ST + DFO, and ST alone; #P < .05 versus corresponding groups ST + gallium, ST + DFO, and ST alone; ‡P < .05
versus corresponding groups ST + DFO and ST alone.
icant differences were found among any of the study
groups. Table II and Fig 2 show the postischemic
recovery of cardiac function and the duration of fibril-
lation from the onset of reperfusion until spontaneous
conversion to sinus rhythm. Protection by intermittent
administration of unsupplemented ST (ST alone, pro-
tocol 1) resulted in 29.8% ± 0.5% recovery of aortic
flow when compared with the preischemic value (Fig
2). When hearts were protected with ST alone accord-
ing to protocol 2, however, aortic flow recovery was
reduced (8.0% ± 4.0%; P < .05). With protocol 1, sig-
nificant improvement was observed when ST was sup-
plemented with DFO, zinc, and gallium. Using the
combination of zinc-DFO and also gallium-DFO, aor-
tic flow recovery rates were even superior (P < .05) to
those obtained by supplementation of DFO, zinc, or
gallium alone. The same pattern was observed when
protocol 2 was used: The highest recoveries of aortic
flow were measured in hearts protected by ST supple-
mented with zinc-DFO or gallium-DFO. The recovery
rates of the parameters maximum left ventricular devel-
oped pressure and dP/dtmax mirrored the aortic flow
data such that protection by intermittent unsupplement-
ed ST (protocol 1) resulted in significantly improved
recovery when compared with the corresponding group
using protocol 2. With the latter protocol, any of the
supplements to the baseline cardioplegic solution led to
significant improvement of both maximum left ventric-
ular developed pressure and dP/dtmax. Even unsupple-
mented cardioplegic solution administered according
to protocol 1 resulted in recovery rates of these 2 pa-
rameters as high as 71.1% and 73.7%. When this pro-
tocol was used, no further improvement was observed
with any of the supplements tested. 
Except for 1 group (ST alone, protocol 2), postis-
chemic recovery of heart rate measured between 76.8%
and 92.0%. No statistically significant differences were
observed among any of the experimental groups.
Postischemic recoveries of coronary flow ranged
between 47.7% and 94.8% of preischemic values.
Group-dependent numeric differences in mean values
of coronary flow recovery failed to reach statistical sig-
nificance. All hearts defibrillated spontaneously within
10 minutes of Langendorff reperfusion after 2 hours of
global hypothermic ischemia. With protocol 1, supple-
mentation of the cardioplegic solution with DFO, zinc,
zinc-DFO, gallium, and gallium-DFO reduced the
duration of postischemic fibrillation significantly when
compared with the time span measured with the use of
the unsupplemented variant. The same pattern was
observed with protocol 2. Each supplement to baseline
cardioplegic solution resulted in a significant reduction
of the postischemic fibrillation period. Administration
of DFO in its complexes with zinc or gallium further
reduced the mean values of the fibrillation periods
when compared with the supplementation with zinc,
gallium, or DFO alone. However, these numeric differ-
ences in mean values were not statistically significant.
Creatine kinase leakage. There was no significant
difference in the preischemic baseline creatine kinase
leakage among any of the experimental groups (Table
III). When compared with preischemic values, immedi-
ate postischemic creatine kinase leakage was increased
in all experimental groups. All supplements to cardio-
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Table II.  Postischemic functional recovery rates and duration of fibrillation during the initial phase of reperfusion
after 2 hours of global ischemia at 10°C 
Maximum LVDP dP/dtmax Heart rate Coronary flow Fibrillation 
Group (%) (%) (%) (%) (s)
Protocol 1
ST alone 71.1 ± 9.5 73.7 ± 2.2† 76.8 ± 3.1 82.0 ± 5.1 180 ± 13
ST + DFO 83.7 ± 1.5 74.2 ± 3.9 85.2 ± 2.8 92.2 ± 2.6 126 ± 15*
ST + Zn 80.0 ± 2.8 76.4 ± 3.5 87.6 ± 4.9 89.9 ± 2.7 134 ± 12*
ST + Zn-DFO 86.4 ± 2.1 82.6 ± 2.7 90.4 ± 1.1 94.8 ± 2.0 116 ± 14*
ST + Ga 81.2 ± 1.9 72.2 ± 3.3 88.0 ± 2.6 83.0 ± 4.1 139 ± 9*
ST + Ga-DFO 80.4 ± 1.0 76.3 ± 3.2 85.4 ± 3.6 86.8 ± 3.7 106 ± 10*
Protocol 2
ST alone 40.2 ± 15.4 30.3 ± 10.7 42.1 ± 16.7 47.7 ± 18.9 278 ± 39
ST + DFO 81.5 ± 1.1 69.2 ± 2.3* 87.6 ± 3.6 89.7 ± 2.1 116 ± 6*
ST + Zn 79.0 ± 2.8 79.2 ± 2.2* 83.8 ± 6.5 85.9 ± 2.9 129 ± 12*
ST + Zn-DFO 89.4 ± 1.5* 79.7 ± 3.5* 84.3 ± 3.9 91.5 ± 2.1 113 ± 9*
ST + Ga 82.5 ± 1.6 69.2 ± 5.9* 92.0 ± 1.7 91.0 ± 3.7 110 ± 8*
ST + Ga-DFO 79.2 ± 1.6 70.5 ± 2.6* 82.7 ± 2.5 86.3 ± 2.7 98 ± 7*
For legend see Table I.
*P < .05 versus corresponding ST-alone group.
†P < .05 versus ST-alone group (protocol 2).
plegic solution with the exception of zinc alone were
found to be associated with significantly smaller
increases of creatine kinase leakage during reperfusion
in the Langendorff mode. This observation was inde-
pendent of the protocol used. The lowest creatine
kinase concentrations were measured in effluents from
hearts protected by ST supplemented with zinc-DFO
and gallium-DFO. Subsequent reperfusion in the work-
ing heart mode was accompanied by a marked decrease
in the creatine kinase leakage in all experimental
groups. During this period, no significant differences
were observed among any of the study groups.
Study II 
HPLC analyses. Table IV summarizes the HPLC
measurements of malondialdehyde, ascorbic acid, oxy-
purine, and nucleoside in hearts subjected to regional or
global ischemia. Group 1 comprises results from non-
ischemic baseline controls, whereas hearts in groups 3
and 5 were treated with gallium-DFO complex. Hearts
in groups 2 and 4 served as ischemic controls perfused
with unsupplemented perfusate.
Regional ischemia accomplished by temporary
occlusion of the left anterior descending coronary
artery and subsequent reperfusion with unsupplement-
ed perfusate resulted in an increase in tissue malondi-
aldehyde levels from 0.047 to 0.240 µmol/g dry weight
(P < .05). This increase was coupled with a decrease in
tissue ascorbic acid levels from 1.191 to 0.079 µmol/g
dry weight. In addition, regional ischemia went along
with a marked decrease in myocardial concentrations
of the energy-rich phosphates ATP, ADP, and guanosine
triphosphate, whereas catabolites of the former, such as
xanthine and adenosine, were increased in concentra-
tion. When the perfusate was supplemented with galli-
um-DFO, however, ischemia-induced changes were
significantly less pronounced with regard to malondi-
aldehyde, uric acid, inosine, ATP, ADP, and adenosine.
Similar results were obtained in hearts subjected to
global ischemia: malondialdehyde levels increased
after 35 minutes of normothermic ischemia, again cou-
pled with a decrease in postischemic concentrations of
ascorbate. Tissue concentrations of ATP and ADP
decreased after ischemia and subsequent reperfusion.
Accordingly, xanthine and adenosine were found to be
markedly increased. Supplementation of the gallium-
DFO complex during the perfusion periods caused a
tendency toward a reverse in these ischemia-associated
changes. For example, the malondialdehyde levels
increased from a basal tissue concentration of 0.047 to
0.892 µmol/g dry weight after 35 minutes of global
ischemia, whereas this increase was only half as pro-
nounced in the presence of the gallium-DFO complex.
Discussion
DFO alone and in its complexes with zinc or galli-
um were assessed for cardioprotective properties in
isolated perfused rat hearts. The use of zinc-DFO and
gallium-DFO as additives to crystalloid cardioplegic
solution enhanced postischemic functional recovery
in the working heart model, attenuated creatine kinase
leakage, and shortened the duration of ventricular fi-
brillation during reperfusion after global hypothermic
ischemia. Treatment with gallium-DFO proved to
reduce postischemic tissue malondialdehyde levels,
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Table III. Creatine kinase leakage during the preischemic and postischemic perfusion periods
Preischemic, working heart Postischemic, Langendorff Postischemic, working heart 
Group (IU/5 min/heart) (IU/5 min/heart) (IU/5 min/heart)
Protocol 1
ST alone 0.25 ± 0.01 0.93 ± 0.08 0.38 ± 0.03
ST + DFO 0.25 ± 0.01 0.62 ± 0.3* 0.20 ± 0.01
ST + Zn 0.29 ± 0.02 1.10 ± 0.13 0.43 ± 0.03
ST + Zn-DFO 0.26 ± 0.01 0.42 ± 0.02† 0.28 ± 0.02
ST + Ga 0.24 ± 0.01 0.63 ± 0.04* 0.35 ± 0.03
ST + Ga-DFO 0.23 ± 0.01 0.53 ± 0.05* 0.29 ± 0.02
Protocol 2
ST alone 0.24 ± 0.01 1.05 ± 0.09 0.52 ± 0.06
ST + DFO 0.23 ± 0.01 0.63 ± 0.05* 0.24 ± 0.02
ST + Zn 0.27 ± 0.02 0.90 ± 0.05 0.41 ± 0.03
ST + Zn-DFO 0.23 ± 0.01 0.43 ± 0.02† 0.25 ± 0.01
ST + Ga 0.23 ± 0.04 0.63 ± 0.03* 0.31 ± 0.01
ST + Ga-DFO 0.24 ± 0.01 0.52 ± 0.06* 0.32 ± 0.03
For legend, see Table I.
*P < .05 versus corresponding group ST alone. 
†P < .05 versus corresponding groups ST alone, ST + DFO, and ST + Zn.
which were measured as an index of lipid peroxida-
tion. The results suggest (1) that the use of DFO in its
complex with zinc and gallium affords additional pro-
tection when compared with the effects of the single
components alone and (2) that this effect is due to
reduced postischemic generation of oxygen-derived
intermediates.
Previous studies have implicated an important role of
reactive oxygen-derived intermediates such as the super-
oxide anion, hydrogen peroxide, and the hydroxyl radical
in myocardial injury resulting from ischemia and sub-
sequent reperfusion.1 The conversion of superoxide
anion radicals to the highly reactive hydroxyl radicals
is thought to require trace amounts of redox-active
transition metals such as iron and copper via the metal
catalyzed Haber-Weiss reaction.3 The burst of iron and
copper ions we observed previously on postischemic
resumption of coronary flow supports this hypothesis
and is in accord with the increase of hydroxyl radical
activity in postischemic tissues.18 A specific chelator
for transition metal ions such as DFO can tightly bind
both ions, thereby modulating their redox potential.
This pull-out mechanism explains the organ protective
properties of DFO and other chelators of iron that we
and others have described before.5,19 The data present-
ed here support these findings in that supplementation
of ST solution with 100 µmol/L DFO leads to signifi-
cant improvement of postischemic myocardial function
and reduction of ischemic injury in isolated working rat
hearts.
Another strategy for prevention of hydroxyl radical
formation is to displace traces of transition metals of
their binding sites in the metal-catalyzed reaction by
adding redox-inactive agents such as zinc ions or galli-
um ions to the system. These ions compete for the
binding sites of redox-active iron ions, displace them,
and divert the site of free radical production. We and
others have found that zinc exerts antiarrhythmic
effects, inhibits the site-specific formation of radicals
catalyzed by transition metals, and improves myocar-
dial protection of isolated rat hearts.8,20,21 Our present
findings support these observations in that supplemen-
tation of zinc to the baseline cardioplegic solution
improved recovery of postischemic aortic flow and
shortened the duration of postischemic fibrillation
when compared with the results with unsupplemented
cardioplegic solution. 
Even though the role of zinc in myocardial ischemia
is not fully understood, the various data sets suggest
that resident zinc ions disclose an endogenous protec-
tive effect against organ damage induced by oxygen-
derived free radicals and that there is an increased
requirement for zinc in the postischemic heart.22 In
human beings, plasma zinc levels were found to be
reduced after acute myocardial infarction.23 In experi-
mental models involving organ ischemia, an increased
uptake of zinc into mitochondria and microsomal frac-
tions, both possible sites of production of reactive oxy-
gen-derived intermediates, has been observed.24
The effects of gallium, another redox-inactive ion
species, on the cardiovascular and other organ systems
have been studied less intensively. Gallium nitrate is
effective in the treatment of hypercalcemia and
advanced neoplasia.25,26 It also inhibits norepineph-
rine-induced contractions in rabbit aortic strips but
does not affect those elicited by high potassium solu-
tion.27 Millart and coworkers28 observed that adminis-
tration of GaCl3 improves cardiac function in normox-
ic isolated rat hearts. Interestingly, GaCl3 was shown to
decrease the free radical production in neonatal rat
heart cells exposed to oxidative stress.9 In accordance
with our results with zinc, protection by baseline car-
dioplegic solution supplemented with gallium was fol-
lowed by significant improvement of postischemic
recovery of aortic flow and reduction of ischemic
injury when compared with the use of unsupplemented
cardioplegic solution. Similar biochemical properties
of zinc and gallium suggest the same pathway of com-
petitive iron and copper replacement, and our own
observations support previous results indicative of the
cardioprotective properties of both ion species. 
Rather than assessment of zinc, gallium, and DFO
alone, our purpose was to reveal whether administra-
tion of DFO in its complex with zinc and also gallium
acts synergistically in terms of myocardial protection
by virtue of the combined effects of the push-and-pull
mechanisms.7 The proposed site of its action is inter-
ference with the transition metal-dependent generation
of hydroxyl radicals. The “pull” component of the pro-
tection by zinc-DFO (and likewise gallium-DFO) is
achieved by the chelation of ferric iron ions by DFO.
Fe+3 has very high affinity for DFO so that Fe+3 (avail-
able) + zinc-DFO results in Fe-DFO + zinc+2. The
“push” part of the protective effect is attained through
the action of the non-DFO zinc on other sites where
redox-active metal ions reside. Thus, additional Fe+3,
and possibly Cu+2, can be displaced from their sites by
the previously “liberated” zinc ions. Because zinc is
not redox-active, this is expected to further reduce
hydroxyl radical formation. In addition, the combina-
tion of zinc or gallium with DFO has another potential
advantage: DFO, in itself, is a relatively large and ran-
domly oriented molecule with low ability to penetrate
into cells. On metal binding, however, DFO within its
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complexes with zinc or gallium assumes a well-defined
globular structure.29 This alteration is expected to ren-
der these complexes more permeable into cells than the
metal-free species.7 In noncardiac test systems involv-
ing free radical–induced injury triggered by radiation
or alkali burn, we were able to prove the protective effi-
cacy of the push-and-pull mechanism using both zinc-
DFO and gallium-DFO with regard to hydroxyl radi-
cal–induced tissue damage.10-13,30 In compliance with
these results, use of zinc-DFO enhanced functional
recovery of isolated rat hearts after normothermic
ischemia.31 To date, no study has been done on the
effects of DFO in its complexes with zinc or gallium
involving hypothermic myocardial ischemia, such as
hearts frequently undergo during routine cardiac
surgery. Thus, we used 2 protocols of hypothermic car-
diac arrest. Protocol 1 represented an in vitro model of
intermittent cardioplegic perfusion during hypothermic
ischemia, whereas protocol 2 served as a model of
hypothermic arrest with initial induction by administra-
tion of cardioplegic solution and no further interven-
tions except for a single-shot washout directly before
reperfusion. Intermittent application of unsupplement-
ed ST afforded superior recovery of functional parame-
ters as compared with recovery rates obtained after its
application according to protocol 2. This result is com-
patible with the findings of others that multidose regi-
mens using this solution during ischemic intervals up to
2 hours lead to drastic improvement of functional and
metabolic recovery when compared with single-dose
applications. It was suggested that the reinfusions help
to wash out acid metabolites that inhibit anaerobic
metabolism, replace substrate, and maintain an ideal
pH for continued metabolism at a low temperature.32 In
accordance with the data obtained with unsupplement-
ed ST, the numeric mean values of the functional
recovery rates tended to be higher with experimental
protocol 1, regardless of the modifications of the base-
line cardioplegic solution. This result is also indicative
of the superiority of the multidose regimen. 
The recovery rates of the parameter aortic flow were
constantly lower than those of other parameters (maxi-
mum left ventricular developed pressure and dP/dtmax).
Compared with the latter, however, the regeneration of
aortic flow appears more reliable because hearts can
generate a considerable rate of recovery in developed
pressure, which still may not be high enough to over-
come the afterload imposed in a working heart system.
This connection also explains the dissociation of the
relatively high recovery rates in maximum left ventric-
ular developed pressure and dP/dtmax from lower
recoveries in aortic flow. 
Study I clearly demonstrates that both the zinc-DFO
complex and the gallium-DFO complex significantly
improve functional recovery after 2 hours of global
hypothermic ischemia when compared with the protec-
tive effects of either constituent alone. Protection
enhancement is very likely to result from a combina-
tion of push-and-pull mechanisms, thereby preventing
site-specific metal-mediated oxidative tissue damage.
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Table IV. HPLC analyses of metabolites from isolated rat hearts after reperfusion after regional and global
ischemia
No ischemia Regional ischemia Global ischemia
Baseline Control Ga-DFO Control Ga-DFO
(group 1, n = 4) (group 2, n = 7) (group 3, n = 5) (group 4, n = 3) (group 5, n = 4)
MDA 0.047 ± 0.006 0.240 ± 0.014* 0.104 ± 0.027† 0.892 ± 0.010 0.497 ± 0.088
Ascorbic acid 1.191 ± 0.489 0.079 ± 0.020* 0.124 ± 0.036 0.562 ± 0.035 1.532 ± 0.169
ATP 27.69 ± 1.20 7.150 ± 0.590* 13.15 ± 0.970† 3.913 ± 0.499 4.889 ± 0.710
ADP 8.760 ± 0.130 4.030 ± 0.200* 5.660 ± 0.450† 3.694 ± 0.192 2.749 ± 0.148
AMP 0.566 ± 0.021 0.670 ± 0.070 0.900 ± 0.080 2.095 ± 0.295 0.518 ± 0.114
Adenosine 0.110 ± 0.015 1.025 ± 0.106* 0.669 ± 0.114† 0.683 ± 0.083 0.395 ± 0.017
∑A 37.02 ± 1.350 11.85 ± 0.860* 19.71 ± 1.500† 9.697 ± 0.986 8.156 ± 0.971
Energy charge 0.870 ± 0.003 0.770 ± 0.060 0.810 ± 0.060 0.590 ± 0.060 0.770 ± 0.100
Inosine 0.037 ± 0.012 0.775 ± 0.098* 0.397 ± 0.022† 6.540 ± 1.553 5.465 ± 0.606
Hypoxanthine 0.043 ± 0.005 0.385 ± 0.072* 0.171 ± 0.068 0.300 ± 0.015 0.131 ± 0.023
Xanthine 0.023 ± 0.001 0.373 ± 0.067* 0.231 ± 0.062 1.340 ± 0.107 0.986 ± 0.070
Uric acid 0.014 ± 0.004 0.132 ± 0.024* 0.056 ± 0.010† 0.323 ± 0.007 0.152 ± 0.024
Data are given in micromoles per gram of dry weight. HPLC, High-performance liquid chromatography; MDA, malondialdehyde; ATP, ADP, and AMP, adenosine
triphosphate, diphosphate, and monophosphate.
*P < .05 versus nonischemic baseline levels (baseline). 
†P < .05 versus controls (regional ischemia). 
This thesis is strongly supported by measurements of
reduced malondialdehyde levels in hearts of study II
treated with gallium-DFO. Malondialdehydes originate
from an oxygen-derived free radical–mediated break-
down of phospholipids and represent a possible quan-
tifiable marker of molecular damage occurring on
reperfusion. Not surprisingly, concentration changes in
malondialdehydes were found to be coupled to an
increase in the antioxidative capacity as measured by
tissue ascorbate levels (Table IV). Above that, as
response to oxygen and substrate deprivation, nor-
mothermic ischemia leads to the typical concentration
changes in energy-rich phosphates and their dephos-
phorylated catabolites such as oxypurines and nucleo-
tides. 
The concentrations of DFO in complex with zinc or
gallium selected in studies I and II were low (5
µmol/L) when compared with those for treatment
with the single components (DFO, 50 µmol/L; zinc-
histidinate, 30 µmol/L; gallium-nitrate, 100 µmol/L).
Concentrations were selected in view of previous evi-
dence that zinc-DFO and gallium-DFO are effective
in a range between 5 and 30 µmol/L whereas zinc
alone and DFO alone are effective only in much high-
er concentrations.8,10,33
Limitations of the study
There are many obvious differences between the iso-
lated perfused rat heart and the human heart in situ. The
limitations of this type of perfusion system include the
lack of a physiologic peripheral component and aspects
of metabolic, nervous, and hormonal control because
aqueous solutions free of red cells, protein, and fatty
acids are used to perfuse the coronary arteries. In addi-
tion, the time of reperfusion is limited as is the time for
postischemic observations. 
It was our purpose to focus independently on func-
tional effects in the one study and on changes in metab-
olism in the other. The fact that studies I and II were
conducted in laboratories using different equipment,
protocols, and rat strains, however, may limit the com-
parability of results even though appropriate controls
have been used in each set of experiments.
Conclusions
On the basis of the considerable impact of transition
metals on the generation of oxygen-derived free radical
formation, we have observed that the iron chelator
DFO and nonredox active ions such as zinc and galli-
um enhance postischemic myocardial function when
added to baseline cardioplegic solution. The results
obtained with DFO in its complexes with zinc or galli-
um were even superior to the recovery rates achieved
with either of the components alone. Previous evidence
from studies on the protective effects of DFO in its
complexes with zinc or gallium and our measurements
of metabolic changes representing sequelae of oxida-
tive tissue damage suggest an antioxidative synergism
of the push-and-pull mechanism to be involved in the
current findings.10-13,33 Whether this new approach to
myocardial protection will find clinical usefulness dur-
ing postischemic reperfusion of the heart or in cardio-
plegic solutions remains to be determined. 
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